Recent Updates on CDK4/6 Inhibitors for HR-Positive, HER2-Negative Metastatic Breast Cancer

home / insights / recent-updates-on-cdk46-inhibitors-for-hr-positive-her2-negative-metastatic-breast-cancer

Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.

EP. 1: Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

June 15th 2022

Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.

EP. 2: HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

June 15th 2022

Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.

EP. 3: Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

June 22nd 2022

Shared insight on how best to select frontline therapy, alone or in combination, for patients with HR+/HER2- mBC.

EP. 4: PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

June 22nd 2022

Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.

EP. 5: MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

June 29th 2022

Highlights from the MONALEESA-2 and -3 trials combining frontline ribociclib with endocrine therapy in patients with HR+/HER2- metastatic breast cancer.

EP. 6: MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

June 29th 2022

Expert perspectives on the pooled analysis from MONARCH 2 and MONARCH 3, combining frontline abemaciclib with fulvestrant.

EP. 7: HR+/HER2- Metastatic Breast Cancer: Selecting From Approved CDK4/6 Inhibitors

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

July 6th 2022

Richard Finn, MD, considers data behind all three approved CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer and how they compare.

EP. 8: Importance of Molecular Testing in HR+/HER2- Metastatic Breast Cancer

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

July 6th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

EP. 9: HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

July 13th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

EP. 10: Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

July 13th 2022

Key opinion leaders share insight on various mechanisms of resistance to frontline therapy in patients with HR+/HER2- metastatic breast cancer.

EP. 11: Overcoming Resistance in HR+/HER2- mBC: Novel ADC and SARM Therapy

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

July 20th 2022

Considerations for how novel antibody drug conjugates (ADCs) and selective androgen receptor modulators (SARMs) may respectively address mechanisms of resistance within HR+/HER2- metastatic breast cancer.

EP. 12: Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

July 20th 2022

Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.

EP. 13: Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

July 27th 2022

Before closing out their discussion on CDK4/6 inhibition in HR+/HER2- metastatic breast cancer, experts highlight remaining unmet needs in this setting.

EP. 14: HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial Readouts

Massimo Cristofanilli, MD, FACP;Harold Burstein, MD, PhD;Richard Finn, MD

July 27th 2022

Key opinion leaders in breast cancer management share their excitement for data that will be released at the annual ASCO meeting in 2022 or the near future.